Assess whether biosimilarity is analytically justified (392e1b)

Situation

A 505(b)(2) program relying on literature plus a bridging study cannot treat an AdCom briefing document that overstates subgroup findings as color commentary on scientific-advice briefing book. Labeling negotiator must close biosimilarity is analytically justified from that extract under Pharma & Life Sciences / CMC and Development Pathways.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• The population in scientific-advice briefing book is the one an AdCom briefing document that overstates subgroup findings named, so Proceed under protocol follows for this CMC and Development Pathways file.
• The population in scientific-advice briefing book is adjacent only to an AdCom briefing document that overstates subgroup findings; Pause the pathway is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained an AdCom briefing document that overstates subgroup findings before scientific-advice briefing book arrived; no new CMC and Development Pathways path.
• Provenance on scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether scientific-advice briefing book supports the labeled claim labeling negotiator would keep.
• For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against an AdCom briefing document that overstates subgroup findings and write the one fact that would move biosimilarity is analytically justified for labeling negotiator.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings). The follow-on CMC and Development Pathways action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.